References
- Hartley JA. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2021;21(7):931–943. doi: 10.1080/14712598.2020.1776255
- Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634–2645. doi: 10.1182/blood.2020007512
- Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi: 10.1016/S1470-2045(21)00139-X
- Hamadani M, Collins GP, Caimi PF, et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 2021;8(6):e433–e445. doi: 10.1016/S2352-3026(21)00103-4
- Carlo-Stella C, Ansell S, Zinzani PL, et al. S201: Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical hodgkin lymphoma (r/r chl). (Abstract) HemaSphere. 2022;6:102–103. doi: 10.1097/01.HS9.0000843696.37630.1c
- Caimi PF, Ai WZ, Alderuccio JP, et al. Long-term responses with loncastuximab tesirine: updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA Eur Haematol Assoc. 2023 Jun 8-11;7(S3):e402511c. Abstract Frankfurt, Germany Abstract P1132. doi: 10.1097/01.HS9.0000971424.40251.1c
- Kingsley E, Grosicki S, Kwiatek M, et al. Initial safety run-in results of the phase 3 LOTIS-5 trial: novel combination of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL. (Abstract) 10th Annual Meeting of the Society of Hematologic Oncology; 2022 Sep 28 Oct; Houston, TX. Abstract ABCL-320.
- https://ir.adctherapeutics.com/press-releases/press-release-details/2023/ADC-Therapeutics-Announces-Voluntary-Pause-of-Enrollment-in-the-Phase-2-LOTIS-9-Clinical-Trial-of-ZYNLONTA-loncastuximab-tesirine-lpyl-and-Rituximab-in-Unfit-or-Frail-Previously-Untreated-DLBCL-Patients/default.aspx.
- Jain N, Jabbour E, Aldoss I, et al. Adct-602, a CD22 targeting antibody drug conjugate Bound to PBD toxin in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: a phase 1 trial (Abstract) blood. Blood. 2022;140(Supplement 1):521–522. doi: 10.1182/blood-2022-170730
- de Bono JS, Fleming MT, Wang JS, et al. Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide. Clin Cancer Res. 2021;27(13):3602–3609. doi: 10.1158/1078-0432.CCR-20-4528
- Zammarchi F, Havenith KE, Chivers S, et al. Preclinical development of ADCT-601, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting AXL-expressing cancers. Mol Cancer Ther. 2022;21(4):582–593. doi: 10.1158/1535-7163.MCT-21-0715
- Jabeen A, Huang S, Hartley JA, et al. Combination of Camidanlumab Tesirine, a CD25-targeted ADC, with gemcitabine elicits synergistic anti-tumor activity in preclinical tumor Models.(Abstract) blood. Blood. 2020;136(Supplement 1):31–32. doi: 10.1182/blood-2020-137004
- Goldberg AD, Atallah E, Rizzieri D, et al. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020;95:106385. doi: 10.1016/j.leukres.2020.106385
- Fathi AT, Erba HP, Lancet JE, et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018;132(11):1125–1133. doi: 10.1182/blood-2018-03-841171
- Hartley JA, Flynn MJ, Bingham JP, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479. doi: 10.1038/s41598-018-28533-4
- Gregson SJ, Pugh K, Patel N, et al. Efficacy, tolerability, and pharmacokinetic studies of antibody-drug conjugates containing a low-potency pyrrolobenzodiazepine dimer. Mol Cancer Ther. 2022;21(9):1439–1448. doi: 10.1158/1535-7163.MCT-22-0145